Which Is the Better Small-Cap ETF: Vanguard's VBK or Invesco's RZG?

VBK and RZG both posted nearly identical 1-year returns, 43.4% versus 43.1%, but VBK is far cheaper at a 0.05% expense ratio versus 0.35% for RZG. VBK also has much larger AUM at $38.7 billion versus $119.1 million and broader diversification with 579 stocks versus 130 for RZG. RZG is more concentrated in healthcare at 23%, while VBK is split more evenly across technology, industrials, and healthcare.

Analysis

The real signal here is not “small-cap growth” as a factor, but the market’s willingness to pay up for the same exposure despite radically different implementation quality. VBK’s near-identical recent return with far lower fees and far deeper liquidity suggests the marginal buyer is not being compensated for RZG’s added tracking and trading friction; that usually becomes more important in risk-off tapes, when spreads widen and small AUM vehicles can gap away from NAV. The second-order winner is the broader small-cap growth ecosystem inside VBK: more diversified ownership lowers single-name volatility, which can attract asset allocators who otherwise avoid small-cap growth due to idiosyncratic blowups.

The sector mix matters more than the headline category. RZG’s heavier healthcare tilt makes it a more explicit bet on earlier-stage industrial/medtech commercialization and regulatory sensitivity, while VBK’s tech/industrials mix is more levered to capex and order-cycle improvement. That means any macro regime with falling rates and stabilizing PMIs should favor VBK’s broader exposure, whereas RZG only wins if healthcare-specific growth and multiple expansion dominate — a narrower, less reliable path.

For the named holdings, CIEN and CASY are the only obvious marginal beneficiaries in this setup because they sit inside a lower-fee, higher-liquidity wrapper that can absorb incremental flows without forcing price impact. By contrast, the concentrated RZG basket can become a hidden liquidity stress point if growth sells off: annual rebalance and thin AUM can create forced turnover into a less forgiving market, especially if the underlying small-cap complex underperforms larger growth stocks. The consensus is likely underestimating how quickly “cheap enough” passive products become the only acceptable vehicle once volatility rises.

Key Decisions for Investors

• Long VBK / short RZG as a 3-6 month relative-value trade: thesis is fee, liquidity, and diversification will matter more than stock selection if small-cap growth remains choppy; target 3-5% outperformance for VBK with tight stop if RZG takes leadership.
• Buy CIEN and CASY on weakness as cleaner second-order beneficiaries of passive flow into diversified small-cap growth, with a 2-4 month horizon; risk/reward is better than trying to pick concentrated basket winners in RZG.
• Sell upside in RZG via call spreads against a long VBK core if the pair rallies together: the higher-expense, lower-AUM fund has less margin for error and is more vulnerable to spread widening on any volatility spike.
• If rates resume falling and breadth improves, add VBK on pullbacks rather than RZG; the trade is that broader participation should outlast any niche healthcare-led factor burst over the next 6-12 months.
• Avoid initiating fresh long exposure to RZG ahead of market stress events; thin AUM makes it a poor vehicle for tactical risk-on expressions, and liquidity risk can overwhelm factor purity during drawdowns.